Allogene Therapeutics, Inc. · Biotech

ALLO

High riskNext report: Around Nov 5 (est.)

View price ↗

The short version

A company still losing money, with high risk. Institutions are adding.

Going well

No debt reported

Watch out for

About 4 months of cash left at its current burn
Share count growing 15.5% a year (dilution)
Losing money, losses are large next to sales

Money moves

Insiders sold $49K in the last 30 days
Institutions added 70% to their holdings in the quarter ending June 2026 (132 bought, 77 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$1.22-1.6% that day

Company value: $421M; Share price times all shares
Cash vs value: 9%; Cash as a share of company value

From ALLO's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$4.6M

Sep '23Tap a barJun '26

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/5Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-53.4%
PassDebt under half of equityNot relying on borrowed money.No debt reported
MissProfitable every yearSteady profits, not one good year.0 of 8 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$149.6M
MissShare count not growingNot diluting owners. Falling means buybacks.+54.1% in 3 years

Total debt: None; 0.00x equity
Current ratio: 7.93x; short-term assets / bills due
Free cash flow: -$149.6M

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: net margin 10%+, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 12

Revenue: $4.6M
EPS: -$0.13; vs -$0.23
Op. margin: -1011.2%
Free cash flow: -$32.1M
Share count: +50.2%; vs a year ago

Insider rating

Last 90 days

43Mixed

1 insider sold $49K (not pre-planned)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

70/ 100

This week: 2
Normal week: 0.9
vs normal: 2.3x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+69.9%

Institutions added 69.9% to their holdings. 132 bought, 77 sold. 2 quarters of net buying in a row.

Shares held by institutions312.7M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+27.0%

Cash runwayAt last year's cash burn

3 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

345M

Why high risk

Losing money, losses are large next to sales
About 3 months of cash left at its current burn
Share count growing 27% a year (dilution)
2 offering filings in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportAround Nov 5 (est.)Estimated from the same quarter last year

Results filedAug 12
Results filedMay 13
Results filedMar 12
Results filedNov 6, 2025
Results filedAug 13, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (passive)Oct 27 · View filing ↗Big holder 5%+ holder update (active)Sep 30 · View filing ↗Activist 5%+ holder update (passive)Aug 14 · View filing ↗Big holder Shelf offering registrationAug 12 · View filing ↗Offering 5%+ holder update (passive)Aug 7 · View filing ↗Big holder New 5%+ holder (passive)Aug 7 · View filing ↗Big holder Offering prospectusJun 22 · View filing ↗Offering

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$49K1 insider, 0 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER	Sell	36K	$1.34	$49K	1M	Oct 21Filing ↗
-3.4% of their holdings Not a pre-planned sale Filed 2 days after

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

5%+ holder update (passive)Oct 27 · Form SCHEDULE 13G/A ↗

SoldGeoffrey M. ParkerCHIEF FINANCIAL OFFICER

36,342 shares at $1.34 · $49K

-3% of holdings
Now owns 1,045,877 shares
Not a pre-planned sale
Filed 2 days after trade

Oct 21Form 4 ↗

Planned insider saleOct 21 · Form 144 ↗5%+ holder update (active)Sep 30 · Form SCHEDULE 13D/A ↗Leadership changeSep 2 · Form 8-K ↗

SoldEarl Martin DouglasSVP, General Counsel

29,697 shares at $2.12 · $63K

-6% of holdings
Now owns 488,267 shares
Not a pre-planned sale
Filed 4 days after trade

Aug 21Form 4 ↗

Planned insider saleAug 21 · Form 144 ↗EFFECTAug 20 · Form EFFECT ↗5%+ holder update (passive)Aug 14 · Form SCHEDULE 13G/A ↗Earnings resultsAug 12 · Form 8-K ↗Quarterly reportAug 12 · Form 10-Q ↗Shelf offering registrationAug 12 · Form S-3 ↗New 5%+ holder (passive)Aug 7 · Form SCHEDULE 13G ↗5%+ holder update (passive)Aug 7 · Form SCHEDULE 13G/A ↗

Stock awardZachary RobertsPresident and CEO

610,720 shares

Now owns 476,190 shares
Exercise price $2.11
Restricted Stock Unit
2 transactions
Filed 5 days after trade

Jul 1Form 4 ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page